Rigel Pharmaceuticals Files 8-K on Financials
Ticker: RIGL · Form: 8-K · Filed: Mar 5, 2024 · CIK: 1034842
| Field | Detail |
|---|---|
| Company | Rigel Pharmaceuticals Inc (RIGL) |
| Form Type | 8-K |
| Filed Date | Mar 5, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, operations, sec-filing
TL;DR
Rigel Pharma dropped an 8-K on March 5th with financial updates - check the filings for deets.
AI Summary
On March 5, 2024, Rigel Pharmaceuticals, Inc. filed an 8-K report detailing its financial results and operations. The filing provides updates on the company's financial condition and includes financial statements and exhibits. Specific financial figures and operational details are available within the full report.
Why It Matters
This filing provides investors with crucial, up-to-date information on Rigel Pharmaceuticals' financial health and operational performance, impacting investment decisions.
Risk Assessment
Risk Level: medium — 8-K filings are routine disclosures, but the specific financial details within can reveal significant positive or negative developments for the company.
Key Players & Entities
- RIGEL PHARMACEUTICALS, INC. (company) — Registrant
- March 5, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 611 Gateway Boulevard, Suite 900, South San Francisco, CA 94080 (address) — Principal executive offices
- (650) 624-1100 (phone_number) — Registrant's telephone number
FAQ
What specific financial results are detailed in this 8-K filing?
The filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but specific figures are not provided in the summary text.
When was the earliest event reported in this filing?
The earliest event reported was on March 5, 2024.
What is Rigel Pharmaceuticals, Inc.'s state of incorporation?
Rigel Pharmaceuticals, Inc. is incorporated in Delaware.
Where are Rigel Pharmaceuticals, Inc.'s principal executive offices located?
The principal executive offices are located at 611 Gateway Boulevard, Suite 900, South San Francisco, CA 94080.
What is the company's IRS Employer Identification Number?
The IRS Employer Identification Number is 94-3248524.
Filing Stats: 557 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-03-05 16:10:40
Key Financial Figures
- $0.001 — h Registered Common Stock, par value $0.001 per share RIGL The Nasdaq Stock Mar
Filing Documents
- tm247928d1_8k.htm (8-K) — 26KB
- tm247928d1_ex99-1.htm (EX-99.1) — 191KB
- tm247928d1_ex99-1img001.jpg (GRAPHIC) — 12KB
- 0001104659-24-031010.txt ( ) — 425KB
- rigl-20240305.xsd (EX-101.SCH) — 3KB
- rigl-20240305_lab.xml (EX-101.LAB) — 33KB
- rigl-20240305_pre.xml (EX-101.PRE) — 22KB
- tm247928d1_8k_htm.xml (XML) — 4KB
02
Item 2.02. Results of Operations and Financial Condition. On March 5, 2024, Rigel Pharmaceuticals, Inc. (" Rigel ") announced certain financial results for its fourth quarter and year ended December 31, 2023. A copy of Rigel's press release, titled "Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update," is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. The information in this report, including the exhibit hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Rigel, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 99.1 Press Release, dated March 5, 2024, titled "Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update." 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 5, 2024 RIGEL PHARMACEUTICALS, INC. By: /s/ Ray Furey, J.D. Ray Furey, J.D. Executive Vice President, General Counsel and Corporate Secretary